Overview
McDermott Will & Emery advised Owkin, the first TechBio unicorn to use cutting-edge causal AI to accelerate precision drug discovery, development and diagnostics, on an exclusive global license agreement with Idorsia (SIX: IDIA) to develop and commercialize OKN4395, a clinically-ready dual inhibitor of the EP2 and EP4 prostanoid receptors.
This license is part of an AI-driven oncology and immunology drug pipeline leveraging spatial multiomics data via MOSAIC, which enables Owkin to capture the tumor microenvironment in a way that few others can.
The McDermott team advising Owkin included Emmanuelle Trombe, Anne-France Moreau (partners), Lorraine Maisnier-Boché (counsel) and Caroline Noyrez. The team advised Owkin on the license with Idorsia, as well as on the contractual and data protection aspects of the MOSAIC project.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
